NMRA Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of --. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat CEL-SCI Corp.'s return on equity of -266.61%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 406.45%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 836.12%. Given that CEL-SCI Corp. has higher upside potential than Neumora Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Neumora Therapeutics, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than CEL-SCI Corp.'s net income of -$5.7M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of 16.24%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 406.45%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -39.97%. Given that Neumora Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 1.38x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ventyx Biosciences, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of --. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Ventyx Biosciences, Inc.'s return on equity of -45.75%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 406.45%. On the other hand Ventyx Biosciences, Inc. has an analysts' consensus of $15.14 which suggests that it could grow by 62.13%. Given that Neumora Therapeutics, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Ventyx Biosciences, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ventyx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ventyx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Ventyx Biosciences, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Ventyx Biosciences, Inc. quarterly revenues of --. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Ventyx Biosciences, Inc.'s net income of -$22.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Ventyx Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus -- for Ventyx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.